sequence id,run,hcv_wg_pipeline,pipeline_version,sample id,sample date,initial genotype,genotype,subtype,Genotyping CORE,Genotyping E1,Genotyping E2,Genotyping P7,Genotyping NS2,Genotyping NS3,Genotyping NS4A,Genotyping NS4B,Genotyping NS5A,Genotyping NS5B,patient id,treatment id,regime,treatment date,drug id,drug manufacturer,therapy class,city,country of birth,date of birth,diagnosis date,ethnicity,nationality,gender,hiv status
H204820685-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H204820685,23-Sep-2020,-,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,1,71.0,2 tablets per day,08-Aug-2020,dasabuvir,-,-,London,England,08-Apr-1971,08-Dec-2002,White,British,Unknown,No
H210161351-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210161351,17-Feb-2021,2a,2,a,2a,2a,2a,2a,2a,2a,2a,2a,2a,2a,2,,,,,,,Cardiff,Wales,09-Jan-1985,31-Dec-1997,White,British,Unknown,Yes
H210180794-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210180794,06-Jul-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,3,72.0,2 tablets per day,07-Jan-2011,sofosbuvir,Gilead,NS5B nucleotide polymerase inhibitor,Brighton,Italy,12-Mar-1984,17-Apr-1995,Black African,Italian,-,Yes
H210180795-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210180795,25-Nov-2019,1a,Check genotyping results by genes: NULL 1a,-,,1a,1a,1a,1a,1a,1a,1a,1a,1a,3,72.0,2 tablets per day,07-Jan-2011,sofosbuvir,Gilead,NS5B nucleotide polymerase inhibitor,Brighton,Italy,12-Mar-1984,17-Apr-1995,Black African,Italian,-,Yes
H210220700-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210220700,17-Mar-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,5,,,,,,,Belfast,Northern Ireland,06-Nov-1981,26-Sep-1990,Not Stated,British,Other,Yes
H210220788-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210220788,20-Oct-2020,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,7,70.0,1 tablet per day,05-Jun-2019,ritonavir,AbbVie,NS5A inhibitor,London,France,28-Aug-1987,22-Apr-1988,White,Italian,Male,Yes
H210240111-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210240111,08-Feb-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,8,69.0,-,05-Jun-2019,simeprevir,Janssen,NS3A/4A protease inhibitor,-,Russia,23-Jul-2066,23-Jan-1989,White,Russian,Male,Yes
H210240113-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210240113,03-Dec-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,9,7.0,-,05-Apr-2019,ritonavir,AbbVie,NS5A inhibitor,-,Scotland,05-Sep-2042,02-Jul-1995,Black other,British,Unknown,Yes
H210240113-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210240113,03-Dec-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,9,8.0,-,05-Apr-2019,dasabuvir,-,-,-,Scotland,05-Sep-2042,02-Jul-1995,Black other,British,Unknown,Yes
H210220787-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210220787,27-Mar-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,10,5.0,-,05-Jan-1988,ombitasvir,AbbVie,NS5B nucleotide polymerase inhibitor,Edinburgh,Scotland,14-Dec-2067,15-Mar-1998,White,British,Male,No
H210220787-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210220787,27-Mar-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,10,4.0,-,30-Jun-2011,ledipasvir,Gilead,NS5A inhibitor,Edinburgh,Scotland,14-Dec-2067,15-Mar-1998,White,British,Male,No
H210220787-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210220787,27-Mar-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,10,6.0,-,30-Jun-2011,paritaprevir,AbbVie,NS3A/4A protease inhibitor,Edinburgh,Scotland,14-Dec-2067,15-Mar-1998,White,British,Male,No
H210241030-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210241030,28-Apr-2019,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,10,5.0,-,05-Jan-1988,ombitasvir,AbbVie,NS5B nucleotide polymerase inhibitor,Edinburgh,Scotland,14-Dec-2067,15-Mar-1998,White,British,Male,No
H210241030-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210241030,28-Apr-2019,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,10,4.0,-,30-Jun-2011,ledipasvir,Gilead,NS5A inhibitor,Edinburgh,Scotland,14-Dec-2067,15-Mar-1998,White,British,Male,No
H210241030-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210241030,28-Apr-2019,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,10,6.0,-,30-Jun-2011,paritaprevir,AbbVie,NS3A/4A protease inhibitor,Edinburgh,Scotland,14-Dec-2067,15-Mar-1998,White,British,Male,No
H210280185-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210280185,14-Jul-2019,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,11,,,,,,,London,England,04-Oct-2043,19-Jul-1988,White,British,Other,No
H210280208-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210280208,28-Mar-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,12,9.0,-,08-Aug-2020,ritonavir,AbbVie,NS5A inhibitor,London,Russia,20-Oct-2053,30-May-2004,White,Russian,Unknown,Yes
H210281395-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210281395,21-May-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,13,,,,,,,London,England,27-Feb-2046,12-Jul-1992,White,British,Male,No
H210281396-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210281396,07-Oct-2019,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,14,,,,,,,London,England,01-Feb-1989,08-Mar-1990,White,British,Unknown,No
H210281397-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210281397,27-Jan-2021,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,15,66.0,-,05-Jun-2019,simeprevir,Janssen,NS3A/4A protease inhibitor,London,England,22-Sep-2066,03-Feb-2004,White,British,Female,No
H210281397-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210281397,27-Jan-2021,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,15,68.0,1 tablet per day,07-Jan-2011,ombitasvir,AbbVie,NS5B nucleotide polymerase inhibitor,London,England,22-Sep-2066,03-Feb-2004,White,British,Female,No
H210281397-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210281397,27-Jan-2021,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,15,67.0,1 tablet per day,30-Jun-2011,simeprevir,Janssen,NS3A/4A protease inhibitor,London,England,22-Sep-2066,03-Feb-2004,White,British,Female,No
H210281398-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210281398,11-Jan-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,16,,,,,,,London,England,07-Jul-2043,20-Dec-1997,Not Stated,British,Male,Yes
H210281399-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210281399,18-Apr-2019,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,17,,,,,,,Glasgow,Scotland,29-Jul-2050,18-Sep-1996,White,British,Other,Yes
H210300532-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210300532,22-Mar-2020,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,18,,,,,,,Gibraltar,Gibraltar,18-May-2068,11-Apr-1994,Other/Mixed,British,Female,Yes
H210300533-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210300533,06-Aug-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,19,,,,,,,Glasgow,Scotland,05-Aug-2054,19-Jun-2002,Asian,British,Other,Yes
H210300549-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210300549,28-May-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,19,,,,,,,Glasgow,Scotland,05-Aug-2054,19-Jun-2002,Asian,British,Other,Yes
H210300550-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210300550,17-May-2019,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,21,,,,,,,Sheffield,Ghana,05-Feb-2060,31-May-2004,Asian,British,Female,Yes
H210300551-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210300551,27-Mar-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,22,,,,,,,-,-,03-May-1978,07-Oct-2003,White,Unknown,Unknown,Yes
H210341088-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210341088,21-Sep-2020,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,23,,,,,,,London,-,03-Sep-2043,12-Aug-1996,White,-,Other,No
H210360996-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210360996,31-Jan-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,24,1.0,1 tablet per day,05-Apr-2019,simeprevir,Janssen,NS3A/4A protease inhibitor,London,-,04-Oct-2055,27-Jul-1996,White,Others,Other,No
H210360996-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210360996,31-Jan-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,24,2.0,1 tablet per day,05-Apr-2019,sofosbuvir,Gilead,NS5B nucleotide polymerase inhibitor,London,-,04-Oct-2055,27-Jul-1996,White,Others,Other,No
H210360996-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210360996,31-Jan-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,24,3.0,2 tablets per day,08-Aug-2020,dasabuvir,-,-,London,-,04-Oct-2055,27-Jul-1996,White,Others,Other,No
H210360997-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210360997,26-Sep-2019,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,25,,,,,,,-,-,31-Dec-1980,27-Aug-1992,White,Others,Male,Yes
H210360998-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210360998,08-Feb-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,26,,,,,,,-,England,16-Jan-1982,16-Jun-1989,White,British,Other,No
H210360999-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210360999,03-Jul-2019,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,27,,,,,,,London,Brazil,21-Feb-2048,14-Jul-1996,White,Brazilian,-,No
H210361033-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210361033,24-May-2019,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,28,,,,,,,London,Portugal,13-Dec-1988,26-Oct-1991,White,Portuguese,Male,No
H210380210-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210380210,20-Sep-2020,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,29,,,,,,,Manchester,England,16-Dec-2051,10-Nov-1994,White,British,Male,Yes
H210380784-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210380784,29-Mar-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,30,,,,,,,London,China,19-Apr-2060,01-Jul-1993,White,Chinese,Female,Yes
H210380785-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210380785,13-Jan-2021,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,31,,,,,,,Salisbury,USA,04-Apr-2068,23-Jan-1988,White,British,Female,Yes
H210380825-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210380825,06-Feb-2021,3a,Check genotyping results by genes: NULL 3a,-,,3a,3a,3a,3a,3a,3a,3a,3a,3a,32,,,,,,,-,Russia,16-Nov-2063,10-Mar-2004,White,Russian,Female,Yes
H210400331-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210400331,22-Jul-2019,1b,Check genotyping results by genes: 1 1b,-,1,1b,1b,1b,1b,1b,1b,1b,1b,1b,33,,,,,,,London,Korea,19-May-2067,05-Mar-1988,White,Korean,Male,Yes
H210400388-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210400388,17-Nov-2019,1a,Check genotyping results by genes: 1 1a,-,1,1a,1a,1a,1a,1a,1a,1a,1a,1a,34,,,,,,,-,Ireland,16-Feb-2040,17-Aug-2001,White,Irish,Male,Yes
H210400421-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210400421,04-Jun-2020,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,35,,,,,,,-,Ireland,08-Oct-1984,04-Jul-1993,White,Irish,Male,No
H210400512-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210400512,14-Jul-2020,3a,3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,36,,,,,,,-,Spain,20-May-2056,16-Nov-2005,White,Spanish,Male,No
H210420137-1_genomancer_NGS91,NGS91,Genomacer,v.1,H210420137,09-Sep-2020,3a & 1a (dual infection),3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,37,,,,,,,Cambridge,France,27-Mar-2068,28-Aug-1996,White,French,Male,Yes
H210420137-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210420137,09-Sep-2020,3a & 1a (dual infection),3,a,3a,3a,3a,3a,3a,3a,3a,3a,3a,3a,37,,,,,,,Cambridge,France,27-Mar-2068,28-Aug-1996,White,French,Male,Yes
H210420137-2_genomancer_NGS91,NGS91,Genomacer,v.1,H210420137,09-Sep-2020,3a & 1a (dual infection),Check genotyping results by genes: 1 1a,-,1,1a,1a,1a,1a,1a,1a,1a,1a,1a,37,,,,,,,Cambridge,France,27-Mar-2068,28-Aug-1996,White,French,Male,Yes
H210420662-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210420662,05-Jun-2019,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,38,,,,,,,-,Kenya,25-Jun-2043,23-Dec-1989,White,Kenyan,Male,No
H210420664-1_NGS91,NGS91,PHE HCV bioinformatics pipeline,version 1.0,H210420664,25-Nov-2020,1a,1,a,1a,1a,1a,1a,1a,1a,1a,1a,1a,1a,39,,,,,,,Oxford,South African,11-Feb-2068,23-Jun-1995,Asian,South African,Female,No
